anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: One of the significant changes in intensive care medicine over the past 2 decades is the acknowledgment that improper mechanical ventilation settings substantially contribute to pulmonary injury in critically ill patients. Artificial intelligence (AI) solutions can optimize mechanical ventilation settings in intensive care units (ICUs) and improve patient outcomes. Specifically, machine learning algorithms can be trained on large datasets of patient information and mechanical ventilation settings. These algorithms can then predict patient responses to different ventilation strategies and suggest personalized ventilation settings for individual patients.
OBJECTIVE: In this study, we aimed to design and evaluate an AI solution that could tailor an optimal ventilator strategy for each critically ill patient who requires mechanical ventilation.
METHODS: We proposed a reinforcement learning-based AI solution using observational data from multiple ICUs in the United States. The primary outcome was hospital mortality. Secondary outcomes were the proportion of optimal oxygen saturation and the proportion of optimal mean arterial blood pressure. We trained our AI agent to recommend low, medium, and high levels of 3 ventilator settings-positive end-expiratory pressure, fraction of inspired oxygen, and ideal body weight-adjusted tidal volume-according to patients' health conditions. We defined a policy as rules guiding ventilator setting changes given specific clinical scenarios. Off-policy evaluation metrics were applied to evaluate the AI policy.
RESULTS: We studied 21,595 and 5105 patients' ICU stays from the e-Intensive Care Unit Collaborative Research (eICU) and Medical Information Mart for Intensive Care IV (MIMIC-IV) databases, respectively. Using the learned AI policy, we estimated the hospital mortality rate (eICU 12.1%, SD 3.1%; MIMIC-IV 29.1%, SD 0.9%), the proportion of optimal oxygen saturation (eICU 58.7%, SD 4.7%; MIMIC-IV 49%, SD 1%), and the proportion of optimal mean arterial blood pressure (eICU 31.1%, SD 4.5%; MIMIC-IV 41.2%, SD 1%). Based on multiple quantitative and qualitative evaluation metrics, our proposed AI solution outperformed observed clinical practice.
CONCLUSIONS: Our study found that customizing ventilation settings for individual patients led to lower estimated hospital mortality rates compared to actual rates. This highlights the potential effectiveness of using reinforcement learning methodology to develop AI models that analyze complex clinical data for optimizing treatment parameters. Additionally, our findings suggest the integration of this model into a clinical decision support system for refining ventilation settings, supporting the need for prospective validation trials.
The invention relates to the technical field of medicine, in particular to a stomach floating type pellet and a preparation method thereof. The stomach floating type pellet comprises a pellet core, a drug layer and a sustained-release layer; the density of the pellet is smaller than 1g/cm<3>, so that the drug can float in the stomach, sustainably release the drug ingredients; stomach floating type capsules can be prepared by loading the pellets into capsules. The preparation type is suitable for drugs mainly absorbed in the stomach, in particular to the drugs that are absorbed better in the stomach than in the enteric canal. When the drugs are prepared into stomach floating type pellets or stomach floating type capsules, compared with ordinary preparation, the times of administration is reduced and the relatively stable blood concentration of the drugs is kept in vivo, thus ensuring the sustained release of the drugs, improving the bioavailability and reducing the dosage. At the same time, as the stomach floating type pellet is a granose system, the drug release behavior is the collective behavior of each pellet, so that coating failure of a plurality of pellets can not lead to failure of the whole dosage, thus having higher safety. The sustained-release pellet is prepared by adopting general technique and is easy for realizing industrial production.
A method of stabilising a polypeptide or cytokine solution or suspension by adding an exogenous hydrophobic molecule, preferably a caesin, is claimed. The casein may comprise an   a   and/or a   b   casein or more preferably bovine casein. The cytokine may be an interferon. HuINF-  b   is exemplified. Also claimed is a composition comprising a container with a hydrophobic inner surface coating of casein in contact with a pharmaceutical solution or suspension of a polypeptide. Alternatively claimed is a method of releasing a polypeptide adsorbed to a hydrophobic solid surface by contacting the solid surface with a mixture comprising a casein and incubating the surface with the mixture.
The research will be carried out in a randomized controlled manner. There will be three groups in the research: those who received video (intervention), brochure (intervention) and verbal (control) discharge instructions. A power analysis was performed based on the number of children in both groups, in another study in which the scales to be used in the research were used. According to the calculations made in the G-Power 3.1 Demo package program, when the effect size was accepted as 0.8, it was seen that at least 48 cases in each group would be sufficient for 80% power. Children who meet the research criteria will be assigned a random number to the intervention and control groups via http://www.randomize.org/ by numbering the order of arrival at the hospital. Research data will be collected using Descriptive Information Form and Parental Fever Management Scale and Post-Discharge Data Collection Form.
PURPOSE: In laryngeal squamous cell carcinoma (LSCC) treated with transoral laser microsurgery (TOLMS), the status of margins significantly affected local control. When a positive or close margin is present, there is no ubiquitous consensus regarding further treatments. The rationale of the present systematic review and meta-analysis is to investigate the survival impact of the status of the margins in patients affected by LSCC treated with TOLMS.
DATA SOURCES: PubMed, EMBASE, and Cochrane Library.
METHODS: We performed a systematic search, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Inclusion criteria were: patients affected by LSCC, staged according to the American Joint Committee on Cancer Staging System and treated by TOLMS without any previous treatment; margins status (close, positive, negative) and the adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) of overall survival, disease-specific survival, and disease-free survival has to be reported.
RESULTS: Nine studies were deemed eligible for the qualitative analysis, and 3 for the quantitative analysis to investigate the association between margin status and OS. The cumulative number of patients was 3130. The sample size ranged from 96 to 747 patients. The follow-up period ranged from 0 to 201 months. The meta-analysis results show that positive margins have an aHR of 1.30 yet with CI range (0.56 to 2.97).
CONCLUSIONS: Our current meta-analysis results are unable to definitively assess the real impact of resection margins on OS. Few authors provide accurate data regarding position and types of margins. Further prospective or high-quality studies are required.
Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
BackgroundHaemolytic uremic syndrome (HUS) is a severe complication of infection with Shiga toxin-producing Escherichia coli (STEC). Although the reservoirs of STEC are known, the source of the infection of sporadic cases is often unknown. In 2023, we observed several cases of bloody diarrhoea with STEC infection in children and adolescents returning from vacations.AimWe aimed to explore the association between travel and bloody diarrhoea with STEC infection in children and adolescents.MethodsWe included all children and adolescents with bloody diarrhoea with STEC infection identified in 2023 by the ItalKid-HUS Network surveillance system in northern Italy. We interviewed children's families and sent a questionnaire on recent travels abroad. The exposure time was between 3 days after arrival abroad and 5 days after return home. A self-controlled case series (SCCS) design was used in the analysis.ResultsOf the 43 cases, 11 developed HUS. Twenty-three cases did not travel abroad, while 20 had travelled to several destinations. The incidence rate ratio (IRR) associated with travel to Egypt was 88.6 (95% confidence interval (CI): 17.0-462). Serotype analysis excluded the possibility of a single strain causing the infections. We did not find the source of the infections.ConclusionThere is an elevated risk of acquiring STEC infection with bloody diarrhoea and HUS associated with travel to Egypt. Specific investigations to identify the source are needed to implement effective preventive measures.
Participants randomized to the 20mcg group will receive 20mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 80mcg.
Systems and methods are provided for generating training data for training a neural network. The neural network may be a machine learning model. The neural network may be a U-Net neural network. Training data for training a neural network may be generated by combining X-ray image data and non-X-ray image data. Training data for training a neural network may be generated by superimposing data having a characteristic related to a lesion onto X-ray image data. The superimposed data may be used to simulate calcification features in mammographic images. Processing circuitry is configured to perform noise reduction by inputting an input image of a breast into a trained machine-learning model to output an output image in which noise included in the input image is reduced in the output image while leaving a characteristic of a lesion included in the input image undeleted in the output image.
This was a long-term open-label study of migalastat in participants with Fabry disease who were previously enrolled in a Phase 2 study of migalastat (FAB-CL-201 \[NCT00214500\], FAB-CL-202 \[NCT00283959\], FAB-CL-203 \[NCT00283933\], or FAB-CL-204 \[NCT00304512\]). Participants could enter this extension study immediately upon completion of participation in their previous study of migalastat, or at a later time point. Thus, some participants did not necessarily have continuous treatment with migalastat from the end of the original study to the time of enrollment into this extension study. Participants who enrolled before Protocol Amendment 2 received migalastat 150 milligrams (mg) orally once every other day (QOD). After the amendment, these participants entered a dose escalation period (DEP) at their next scheduled visit. During the DEP, participants received migalastat 250 mg (once daily \[QD\] for 3 days and 4 days off per week) for the first 2 months. If there were no safety concerns, the dose was then increased to 500 mg QD for 3 days and 4 days off per week). Participants received 500 mg (QD for 3 days and 4 days off per week) for up to 10 months, depending on the approval date of the protocol amendments at each site. An interim review of safety and PD data was performed after all enrolled participants had completed at least 4 months of treatment in the DEP. After the review, the dose and regimen of migalastat was returned to 150 mg QOD for all participants, except those who were on another dose as previously agreed by the investigator and medical monitor.

The sponsor (Amicus Therapeutics) discontinued Study FAB-CL-205 for logistical reasons and not due to either safety concerns or lack of efficacy. Participants who were ongoing in Study FAB-CL-205 at the time of discontinuation were offered participation in another open-label, long-term treatment study of migalastat (AT1001-041 \[NCT01458119\]). Participants who did not enroll in Study AT1001-041 were contacted by telephone or another suitable method approximately 1 month after the End of Study (EOS) visit to inquire about adverse events and concomitant medications.
Proanthocyanidin-cinnamaldehydes pyrylium products (FP) were synthesized by the condensation reaction of proanthocyanidins (PAC) with various cinnamaldehydes. Synthesized FP exhibited fluorescence at higher excitation and emission wavelengths than PAC. FP were evaluated for their ability to agglutinate extra-intestinal pathogenic  Escherichia coli  (ExPEC). Results showed that FP were significantly more bioactive (p-value < 0.05) for agglutinating ExPEC compared to PAC. Scanning electron microscopy indicates that FP interacts with ExPEC surface structures and suggests that FP have higher affinity with the fimbriae-like structures on the surface of ExPEC in comparison to PAC. In addition, fluorescent microscopy performed on  in vitro  and  in vivo  agglutination assays show that FP entrap ExPEC in a web-like network, thus demonstrating agglutination of ExPEC. Fluorescent proanthocyanidins offer a new approach to visualize bacterial infections and to treat such infections.
Provided herein are alphavirus vectors derived from South African Arbovirus No. 86 (S.A.AR86) comprising attenuating mutations and methods of making the same. Also provided are improved viral vectors and helper constructs comprising a S.A.AR86 capsid enhancer sequence. The present invention also provides S.A.AR86 replicon and helper constructs comprising an alphavirus capsid enhancer sequence. Further provided are methods of administering an alphavirus vector comprising a heterologous nucleotide sequence (preferably encoding an immunogen or a therapeutic polypeptide) according to the invention to a cell or subject. In preferred embodiments, the alphavirus vector delivers the heterologous nucleotide sequence to the cells of the bone, bone marrow, and/or bone-associated connective tissue.
Nuclear condensates have been shown to regulate cell fate control, but its role in oncogenic transformation remains largely unknown. Here we show acquisition of oncogenic potential by nuclear condensate remodeling. The proto-oncogene SS18 and its oncogenic fusion SS18-SSX1 can both form condensates, but with drastically different properties and impact on 3D genome architecture. The oncogenic condensates, not wild type ones, readily exclude HDAC1 and 2 complexes, thus, allowing aberrant accumulation of H3K27ac on chromatin loci, leading to oncogenic expression of key target genes. These results provide the first case for condensate remodeling as a transforming event to generate oncogene and such condensates can be targeted for therapy. One sentence summary: Expulsion of HDACs complexes leads to oncogenic transformation.
Patients randomized to this group will receive up to12 (minimum 8) sessions of BCI training with the RecoveriX system (gtec, Austria). The system combines EEG driven functional electrical stimulation with visual feedback. BCI training is provided as a part of standard training of the impaired upper limb.
1. Using a 1-mL syringe with needle, withdraw 0.05 to 0.1 mL Indium In 111 Pentetreotide Injection from the Octreoscan Reaction Vial. Apply the preparation to the Sep-Pak cartridge through the longer end of the cartridge. Make sure that the sample is migrating onto the column of the cartridge. Note: After this step, the cartridge and all solutions eluted from it will be radioactive. 
  2. With a disposable 5-mL syringe, slowly (in dropwise manner) push 5 mL water through the longer end of the cartridge, collecting the eluate in a counting vial or tube. Label this eluate as “Fraction 1.” 
  3. Similarly, elute the cartridge with 5 mL methanol. Be sure that this solution is pushed slowly through the longer end of the cartridge so that the elution occurs in a dropwise manner. Collect this fraction in a second culture tube or vial for counting. Label it as “Fraction 2.” Push two 5-mL portions of air through the longer end of the cartridge and collect the eluate with Fraction 2. 
  4. Place the Sep-Pak cartridge in a third culture tube or vial for assay.
This is a retrospective study of 322 patients hospitalized with CSOJ. The socio-demographic and clinical characteristics were recorded. The risk factors for the above two problems were analyzed by logistic regression analysis. Frequency and percentage were used to indicate descriptive research factors. A univariate logistic regression analysis was performed to calculate the odds ratio (OR) and to identify preliminary risk factors. The preliminary risk factors were further identified by multivariate logistic regression analysis.
Childhood obesity is highly prevalent among certain populations of New York. This cross-sectional pilot study examined the associations between parental attitudes about outdoor activities and body mass index (BMI). A questionnaire was distributed among parents of 1 to 13 aged children at ambulatory pediatric clinics. Of 104 children included in the study 57 were of normal weight and 47 were overweight or obese. Most parents of children with BMI <85% reported frequent playground utilization, considered longer hours to spend outside on weekdays, reported a larger total temperature range for outdoor playground utilization and a lower tolerable minimum temperature compared to parents of children with BMI ≥85%, p < .05. Only having a parent born outside of the United States remained a significant predictor of overweight and obesity in the final model. Parents of children with BMI < 85% are more willing to spend time outdoors, regardless of weather. Immigrant parents are protective against overweight.
This is a multicenter, prospective, open-label, randomized, interventional study enrolling patients with indications for permanent cardiac pacing according to the current European Society of Cardiology Guidelines on Cardiac Pacing. All participants will undergo permanent pacemaker implantation for HB or LBB pacing. Subsequently, an invasive electrophysiological study (EPS) and ECANS will be performed. The 2 x 2 randomisation will be performed, i.e. right vs left side superior ECANS and blinded for operator ultrasonography guided effective vs ineffective inferior vagal nerve stimulation). The randomisation will prove the feasibility and efficacy of superior ECANS and feasibility, efficacy, and reproducibility of ultrasonography guided inferior ECANS. All the measured parameters as well as demographic and clinical data will be recorded in the study database. Patients with an exit block or an increase in a pacing threshold of an HB/LBB electrode will be further managed by electrophysiologists from the research group. The management will be based on clinical assessment and patient's decision and may involve pacemaker reprogramming, pacemaker upgrade with a back-up pacing electrode implantation, or cardio-neuro-ablation.
After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
The intervention will consist of 16 Argentine Tango (Tango) sessions, adapted for neurorehabilitation per Hackney and Earhart (2010). Delivered over 8 weeks at a frequency of 2x per week and duration of 1 hour per session, this program teaches the basics steps of partnered Tango dance.
Methods and compositions for preventing an immune response to an immunogenic therapeutic agent [i.e. anti-drug antibody (ADA), a.k.a. anti-therapeutic antibody (ATA)] are disclosed. One of the disclosed methods comprises administering an effective amount of an immunosuppressant such as an IL-2 signaling pathway inhibitor, including an antagonist, super agonist or partial agonist to the cytokine IL-2, to the IL-2 receptor (IL-2R), or to IL-2R signal transduction molecules. Inhibitors can be in the form of antibodies or antibody fragments, peptide inhibitors, fusion molecule, small molecules, antibody/small molecule conjugates. Administration of a given inhibitor can decrease the incidence and/or magnitude of an immune response or prevent an immune response, including an antibody response, to a potentially immunogenic therapeutic agent in a non-human primate (NHP). Some of the disclosed methods produce a tolerizing effect in NHPs.
A consensus peptide of 36 amino acids has been designed which acts as an immunogen raising antibodies against the proteins of all members of the E.coli family CS4-CFA/1. While the N-terminus of members of this family of organisms shows a high degree of identity, the remainder of the sequence of the proteins shows much less homology across the strains. The region of the protein represented in the subunit encompasses known linear B- and T-cell epitopes of CFA/I. The consensus peptide has a high level of homology to strains bearing six different colonization factors. The consensus peptide is of the formula:  VEKNTTVTASVDPTIDLLQADGSALPSAVALTYSPA. An alternative peptide, identified as consensus peptide 2 is of the formula:  VEKNITVTASVDPTIDLLQADGSALPASVALTYSPA.
According to the International Classification of Functioning, Disability, and Health, physical, social, and behavioral environmental factors; can affect a child's disability, activity limitations, and participation. Adapting the environment in which a child with Cerebral Palsy lives or adapting himself according to the environment facilitates independence in daily life activities. There is a need for practical performance tests to evaluate the gait adaptation of children with cerebral palsy in the clinic. However, no study has been found to evaluate gait adaptation in children with cerebral palsy. Therefore, the aim of the study is to evaluate the validity and reliability of the WALK test, which was previously developed for children with special learning disabilities, in individuals with cerebral palsy. The study will be conducted by Afyonkarahisar University Faculty of Health Sciences.
The invention provides a preparation method of cortex meliae effective ingredients. The effective ingredients are obtained through the following steps: carrying out heating extraction, concentration, silicon gel post separation and elution on medical materials; concentrating and drying an elution solution; then, using the prepared liquid chromatogram for continuous separation; collecting the solution; and concentrating and drying the solution. The cortex meliae effective ingredients of the invention can be used as active components, and pharmaceutically acceptable medicine excipients or carriers are added into the effective ingredients to be prepared into preparations according to a method recorded on the pharmacy. The prepared medicine has the preparation forms such as the liquid preparation, the solid preparation, the capsule preparation or the gelatin pearl preparation, and the medication mode is oral medication or injection medication. The cortex meliae effective ingredients provided by the invention can be applied to the medicine for treating and preventing tumors. The preparation method of the invention has the advantages of simple and convenient operation and stable quality. In addition, no report about the liver-tumor-resistance activity of the cortex meliae appears in the prior art, and the invention provides the study basis for developing new cortex meliae anti-tumor medicine.